Equities analysts expect that DURECT Co. (NASDAQ:DRRX) will report sales of $4.60 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for DURECT’s earnings. The lowest sales estimate is $3.00 million and the highest is $7.40 million. DURECT posted sales of $3.52 million during the same quarter last year, which suggests a positive year over year growth rate of 30.7%. The company is scheduled to report its next earnings report on Tuesday, March 13th.
On average, analysts expect that DURECT will report full-year sales of $4.60 million for the current year, with estimates ranging from $32.63 million to $37.03 million. For the next year, analysts anticipate that the business will report sales of $22.67 million per share, with estimates ranging from $14.00 million to $37.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover DURECT.
Several equities research analysts have recently weighed in on the stock. ValuEngine upgraded shares of DURECT from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 10th. HC Wainwright reiterated a “hold” rating on shares of DURECT in a research note on Thursday, November 2nd.
Shares of DURECT (NASDAQ:DRRX) traded down $0.03 on Friday, hitting $1.09. 322,141 shares of the stock traded hands, compared to its average volume of 608,431. DURECT has a twelve month low of $0.74 and a twelve month high of $2.17. The firm has a market capitalization of $166.37, a P/E ratio of -7.27 and a beta of 1.79. The company has a quick ratio of 1.57, a current ratio of 1.67 and a debt-to-equity ratio of 1.46.
A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in DURECT by 590.4% in the fourth quarter. Renaissance Technologies LLC now owns 681,400 shares of the specialty pharmaceutical company’s stock valued at $628,000 after purchasing an additional 582,699 shares during the period. BlackRock Inc. lifted its position in DURECT by 5.8% in the fourth quarter. BlackRock Inc. now owns 9,747,128 shares of the specialty pharmaceutical company’s stock valued at $8,984,000 after purchasing an additional 532,100 shares during the period. Wells Fargo & Company MN lifted its position in DURECT by 12.7% in the fourth quarter. Wells Fargo & Company MN now owns 472,248 shares of the specialty pharmaceutical company’s stock valued at $435,000 after purchasing an additional 53,236 shares during the period. Algert Global LLC acquired a new stake in DURECT in the fourth quarter valued at about $105,000. Finally, SG Americas Securities LLC lifted its position in DURECT by 1,095.1% in the fourth quarter. SG Americas Securities LLC now owns 188,328 shares of the specialty pharmaceutical company’s stock valued at $174,000 after purchasing an additional 172,570 shares during the period. Hedge funds and other institutional investors own 46.84% of the company’s stock.
WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/20/durect-co-drrx-expected-to-announce-quarterly-sales-of-4-60-million.html.
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Get a free copy of the Zacks research report on DURECT (DRRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.